Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D9OS5I
|
|||
| Drug Name |
SB623
|
|||
| Drug Type |
Cell therapy
|
|||
| Indication | Ischemic stroke [ICD-11: 8B11.5Z; ICD-9: 434.91] | Phase 2 | [1] | |
| Traumatic brain injury [ICD-11: NA07.Z] | Phase 2 | [2] | ||
| Company |
SanBio; Sunovion Pharmaceuticals
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT02448641) Study of Modified Stem Cells (SB623) in Patients With Chronic Motor Deficit From Ischemic Stroke (ACTIsSIMA). U.S. National Institutes of Health. | |||
| REF 2 | ClinicalTrials.gov (NCT02416492) A Study of Modified Stem Cells in Traumatic Brain Injury (TBI) (STEMTRA). U.S. National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.